Cellectis S.A. (NASDAQ:CLLS) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. decreased its position in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 14.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 707,630 shares of the biotechnology company's stock after selling 119,618 shares during the quarter. Baillie Gifford & Co. owned 1.27% of Cellectis worth $1,323,000 as of its most recent SEC filing.

Separately, Principal Financial Group Inc. raised its position in Cellectis by 6.2% in the first quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company's stock valued at $1,125,000 after purchasing an additional 24,906 shares during the period. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Stock Up 0.4 %

Shares of Cellectis stock traded up $0.01 during trading hours on Monday, reaching $2.38. 34,481 shares of the company were exchanged, compared to its average volume of 51,257. Cellectis S.A. has a 1 year low of $0.96 and a 1 year high of $3.77. The stock's fifty day moving average is $2.07 and its 200 day moving average is $2.48. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.63 and a current ratio of 1.63. The firm has a market cap of $132.29 million, a PE ratio of -1.84 and a beta of 3.10.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) EPS for the quarter. The firm had revenue of $6.50 million for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. As a group, equities research analysts forecast that Cellectis S.A. will post -0.54 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on CLLS. Oppenheimer cut their target price on Cellectis from $11.00 to $10.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 12th. StockNews.com began coverage on Cellectis in a research report on Sunday. They set a "sell" rating on the stock. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $6.00 price objective on shares of Cellectis in a research report on Friday, May 31st.

Cellectis Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.